Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study (ALADIN)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Mario Negri Institute for Pharmacological Research

ClinicalTrials.gov Identifier:

NCT00309283

First received: March 30, 2006

Last updated: April 23, 2013

Last verified: April 2013

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	January 2012
Primary Completion Date:	January 2012 (Final data collection date for primary outcome measure)

No publications provided by Mario Negri Institute for Pharmacological Research

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P; ALADIN study group. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013 Nov 2;382(9903):1485-95. doi: 10.1016/S0140-6736(13)61407-5. Epub 2013 Aug 21.

To Top